International Journal of Nanomedicine,
Год журнала:
2025,
Номер
Volume 20, С. 125 - 139
Опубликована: Янв. 1, 2025
Photo-immunotherapy
faces
challenges
from
poor
immunogenicity
and
low
response
rate
due
to
hypoxic
microenvironment.
This
study
presents
Rh-PTZ,
a
small
organic
molecule
with
D-π-A
structure,
that
simultaneously
amplifies
mitochondria-targeted
type-I
PDT-dependent
immune
stimulation
for
the
treatment
of
cancer.
The
hydrophobic
Rh-PTZ
was
encapsulated
into
F127
prepare
nanoparticles
(Rh-PTZ
NPs).
ROS
generation
ability,
mitochondrial
targeting
capacity,
ICD
triggering
effect
mediated
by
NPs
under
LED
light
irradiation
were
investigated.
Based
on
4T1
subcutaneous
tumor
model,
in
vivo
biological
safety
assessment,
NIR
fluorescent
imaging,
efficacy
PDT
assessed.
could
efficiently
accumulate
site
induce
O2
•-
•OH
burst
situ
irradiation,
thereby
causing
severe
dysfunction.
can
amplify
stress-caused
immunogenic
cell
death
(ICD)
stimulate
response,
promote
maturation
sufficient
dendritic
cells
(DCs),
enhance
infiltration
cells,
alleviate
immunosuppressive
mitochondria-targeting
holds
promise
photo-immunotherapy
hypoxia
overcoming
limitations
traditional
immunotherapy.
Journal of Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 18, 2025
For
cancer
treatment,
collaborative
strategies
have
been
the
mainstream
for
overcoming
restrictions
resulting
from
monotherapy.
Combining
chemotherapy
with
photodynamic
therapy
(PDT)
has
shown
to
increase
antitumor
effect
and
reduce
side
impacts.
This
study
reports
a
hypoxia-activated
prodrug
BOD-Azo-single
PDT
agent
aniline
mustard
connected
by
azo
bond.
With
light
illumination,
exhibited
some
PDT.
Under
hypoxic
conditions,
bond
cleaved
released
BOD-3-single
of
higher
phototoxicity
chemotoxicity.
In
vivo
therapeutic
experiments
showed
that
significantly
reduced
A375
tumor
proliferation
92%
TGI
value.
Overall,
in
this
study,
was
employed
address
adverse
systemic
toxicity
chemotoxicity
made
up
inefficiency
microenvironment,
introducing
new
strategy
developing
combined
agents
be
advantageous
each
other.
environment,
exerted
strong
synergistic
(CI
=
0.25),
indicating
is
real
bimodal
chemo-photodynamic
agent.
Journal of Nanobiotechnology,
Год журнала:
2025,
Номер
23(1)
Опубликована: Фев. 20, 2025
The
advent
of
nanozymes
has
revolutionized
approaches
to
cancer
diagnosis
and
therapy,
introducing
innovative
strategies
that
address
the
limitations
conventional
treatments.
Nanozyme
nanostructures
with
enzyme-mimicking
catalytic
abilities
exhibit
exceptional
stability,
biocompatibility,
customizable
functions,
positioning
them
as
promising
tools
for
theranostics.
By
emulating
natural
enzyme
reactions,
can
selectively
target
eradicate
cells,
minimizing
harm
adjacent
healthy
tissues.
Nanozymes
also
be
functionalized
specific
targeting
ligands,
allowing
precise
delivery
regulated
release
therapeutic
agents,
improving
treatment
effectiveness
reducing
adverse
effects.
However,
issues
such
selectivity,
regulatory
compliance
remain
critical
challenges
clinical
application
nanozymes.
This
review
provides
an
overview
nanozymes,
highlighting
their
unique
properties,
various
classifications,
activities,
diverse
applications
in
strategic
oncological
deployment
could
profoundly
impact
future
advancements
personalized
medicine,
recent
progress
prospective
directions
enzyme-mimetic
treatment.
summarizes
Materials Horizons,
Год журнала:
2024,
Номер
11(18), С. 4275 - 4310
Опубликована: Янв. 1, 2024
This
comprehensive
review
systematically
summarizes
the
intrinsic
mechanism
of
different
metal
ion
(such
as
Fe
3+
/Fe
2+
,
Cu
/Cu
+
Ca
Zn
Mn
Na
/K
and
Mg
)-mediated
interference
therapies
their
research
progress
in
cancer
treatment.
Chemical Society Reviews,
Год журнала:
2024,
Номер
unknown
Опубликована: Янв. 1, 2024
This
review
provides
a
comprehensive
summary
of
the
dysregulation
redox
metabolism
in
cancer
cells
and
advantages
latest
advances
nanomaterial-assisted
metabolic
regulation
therapy.
Abstract
The
high
heterogeneity
and
severe
side
effects
of
chemotherapy
are
major
factors
contributing
to
the
failure
osteosarcoma
treatment.
Herein,
a
comprehensive
genomic
analysis
is
conducted,
identified
two
prominent
characteristics
osteosarcoma:
significant
cyclin‐dependent
kinases
4
(CDK4)
amplification
homologous
recombination
repair
deficiency.
Based
on
these
findings,
co‐delivery
system
loaded
with
CDK4/6
inhibitors
poly
ADP‐ribose
polymerase
(PARP)
designed.
By
employing
metal–organic
frameworks
(MOFs)
as
carriers,
issue
drug
insolubility
effectively
addressed,
while
also
enabling
controlled
release
in
response
tumor
microenvironment.
To
enhance
targeting
capability
biocompatibility,
MOFs
further
coated
bio‐membrane
B7H3.
This
targeted
biomimetic
possesses
several
key
features:
1)
it
can
precisely
target
B7H3
expression;
2)
combination
PARP
exhibits
synergistic
effects,
significantly
impairing
tumor's
DNA
capacity;
3)
has
potential
for
photodynamic
therapy,
amplifying
defects
maximize
cell
eradication.
Furthermore,
observed
that
this
activate
immune
microenvironment,
increasing
CD8
+
T
infiltration
converting
from
an
immune‐cold
immune‐hot
tumor.
In
summary,
effective
therapeutic
strategy
holds
promise
novel
approach
Frontiers in Pharmacology,
Год журнала:
2024,
Номер
15
Опубликована: Окт. 23, 2024
Photodynamic
therapy
and
ferroptosis
induction
have
risen
as
vanguard
oncological
interventions,
distinguished
by
their
precision
ability
to
target
vulnerabilities
in
cancer
cells.
therapy's
non-invasive
profile
selective
cytotoxicity
complement
ferroptosis'
unique
mode
of
action,
which
exploits
iron-dependent
lipid
peroxidation,
offering
a
pathway
overcome
chemoresistance
with
lower
systemic
impact.
The
synergism
between
photodynamic
is
underscored
the
depletion
glutathione
peroxidase
four
inhibitions
therapy-induced
reactive
oxygen
species,
amplifying
peroxidation
enhancing
ferroptotic
cell
death.
This
synergy
presents
an
opportunity
refine
treatment
modulating
redox
homeostasis.
Porphyrin-based
nanoscale
metal-organic
frameworks
hybrid
structures
exceptional
properties.
These
can
serve
platform
for
integrating
through
carefully
designed
functions.
nanostructures
be
engineered
deliver
multiple
therapeutic
modalities
simultaneously,
marking
pivotal
advance
multimodal
therapy.
review
synthesizes
recent
progress
porphyrin-modified
combined
ferroptosis,
delineating
mechanisms
that
underlie
synergistic
effects
context.
It
underscores
potential
porphyrin-based
advanced
nanocarriers
oncology,
propelling
field
toward
more
efficacious
tailored
treatments.
